Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Pacific Edge shares gain 4% on fourth US deal

Pacific Edge shares gain 4% on fourth US deal

By Suze Metherell

May. 26 (BusinessDesk) - Shares in Pacific Edge gained 4 percent after the biotech company said it had signed a deal with US healthcare provider MultiPlan for the use of its non-invasive bladder cancer test, Cxbladder.

The contract is the largest of the four US healthcare provider Pacific Edge has signed up since October last year, with MultiPlan a preferred provider organisation securing cheaper health rates for insurers for more than 900,000 healthcare providers covering an estimated 68 million people. Its previous three deals covered 62.6 million people.

“Our sales and marketing teams are now focussed on the urologists and clinicians who are treating the largest number of bladder cancer patients to ensure they fully understand the value and benefits that Cxbladder provides to them and their patients” Jackie Walker, chief executive of subsidiary Pacific Edge Diagnostics USA, said in a statement.

It is also "advancing" its relationship with state funded insurer, Centre for Medicare and Medicaid Services, which could potentially give it access to a third of the US population, Walker said.

Pacific Edge shares rose 4 cents to $1.03 in early trading. The stock gained 150 percent last year on news of its US deals, and raised some $20 million to drive sales. Since its March debut on the NZX 50 Index the shares have dropped 58 percent amid a global sell off of growth-orientated tech stocks.

The non-invasive bladder cancer test was adopted by New Zealand district health boards earlier this year.

(BusinessDesk)

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Scoop Business: Fletcher To Close Its Christchurch Insulation Plant, Cut 29 Jobs

Fletcher Building, New Zealand’s largest listed company, will close its Christchurch insulation factory, as it consolidates its Tasman Insulations operations in a “highly competitive market”. More>>

ALSO:

Scoop Business: Novartis Adds Nine New Treatments Under Pharmac Deal

Novartis New Zealand, the local unit of the global pharmaceuticals firm, has added nine new treatments in a far-ranging agreement with government drug buying agency, Pharmac. More>>

ALSO:

Crown Accounts: English Wary On Tax Take, Could Threaten Surplus

Finance Minister Bill English is warning the tax take may come in below forecast in the current financial year, as figures released today confirm it was short by nearly $1 billion in the year to June 30 and English warned of the potential impact of slumping receipts from agricultural exports. More>>

ALSO:

Auckland Outage: Power Mostly Restored Overnight

Vector wishes to advise that all but 324 customers have been restored overnight. These customers are spread throughout the network in small pockets. The main St Johns feeder was restored around midnight allowing most of the customers in all affected areas to have power this morning. More>>

ALSO:

Half Empty: Dairy Prices Drop To Lowest Since August 2009

Dairy product prices fell to the lowest level in more than five years in the latest GlobalDairyTrade auction, led by declines in butter milk powder and whole milk powder. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand

Mosh Social Media
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news